The Discounted Cash Flow (DCF) valuation of Esperion Therapeutics Inc (ESPR) is 3.30 USD. With the latest stock price at 3.18 USD, the upside of Esperion Therapeutics Inc based on DCF is 3.8%.
Based on the latest price of 3.18 USD and our DCF valuation, Esperion Therapeutics Inc (ESPR) is a buy. buying ESPR stocks now will result in a potential gain of 3.8%.
| Range | Selected | |
| WACC / Discount Rate | 5.8% - 7.6% | 6.7% |
| Long-term Growth Rate | 0.5% - 1.5% | 1.0% |
| Fair Price | 2.41 - 4.77 | 3.30 |
| Upside | -24.3% - 49.9% | 3.8% |